Physician profile
Ashley E Cagle
NPI 1265152326
$6,653.80
in general payments reported to CMS, 2019-2025
32 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2023: $2,680 · 2024: $2,589 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,398 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,397.91 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,547.24 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,232.93 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $602.38 | 2022-2025 | Stelara, Tremfya |
| Genzyme Corporation | $405.60 | 2022-2025 | |
| Qol Medical, LLC | $388.76 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $309.16 | 2023-2024 | Linzess |
| Ardelyx, INC. | $249.92 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $249.77 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $235.41 | 2024-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $185.71 | 2022-2024 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $155.38 | 2022-2023 | |
| Evoke Pharma, INC. | $152.08 | 2023-2024 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $121.63 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $115.92 | 2023-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $71.33 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.45 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $57.05 | 2025 | Airsupra |
| Vivus LLC | $56.90 | 2022-2023 | Qsymia |
| Redhill Biopharma INC. | $55.22 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Radius Health, INC. | $52.71 | 2025 | Tymlos |
| Medtronic, INC. | $50.72 | 2022-2024 | Interstim |
| Pfizer INC. | $45.72 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $45.66 | 2023-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.24 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $37.05 | 2023 | Injectafer |
| Celgene Corporation | $23.22 | 2023 | Zeposia |
| Tonix Medicines, INC. | $21.67 | 2025 | Tonmya |
| Braintree Laboratories, INC. | $20.01 | 2023 | Sutab |
| Mallinckrodt Hospital Products INC. | $16.43 | 2023 | Terlivaz |
| Glaxosmithkline, LLC. | $16.34 | 2025 | Benlysta |
| Celltrion USA INC. | $15.39 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $12.80 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.